Get started
MapLight Therapeutics, Inc.MapLight Therapeutics, Inc.MapLight Therapeutics, Inc.

MapLight Therapeutics, Inc.

No trades
No trades
OverviewFinancialsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFs
Full chart
Full chart

Compare with MapLight Therapeutics, Inc.



Key stats


Market capitalization
‪1.70 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.52 USD
Net income (FY)
‪−161.15 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪7.66 M‬
Beta (1Y)
1.37

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
133
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.21 M‬ USD

Profile


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Christopher A. Kroeger
Website
maplightrx.com
Headquarters
Redwood City
Founded
2018
IPO date
Oct 27, 2025
IPO offer price
17.00 USD
ISIN
US56565P1030
CUSIP
56565P103
FIGI
BBG01JZ5DBQ0
Identifiers
ISIN US56565P1030
CFI code
ESVUFR
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


XBI
State Street SPDR S&P Biotech ETF
Weight0.17%
Market value‪19.15 M‬
IWO
iShares Russell 2000 Growth Fund
Weight0.02%
Market value‪3.34 M‬
TMSL
T. Rowe Price Small-Mid Cap ETF
Weight0.09%
Market value‪2.57 M‬
IWC
iShares Microcap ETF
Weight0.09%
Market value‪1.38 M‬
VHT
Vanguard Health Care ETF
Weight0.00%
Market value‪728.00 K‬
LABU
Direxion Daily S&P Biotech Bull 3X ETF
Weight0.14%
Market value‪597.51 K‬
BBC
Virtus Biotech Clinical Trials ETF
Weight0.88%
Market value‪486.86 K‬
VTWG
Vanguard Russell 2000 Growth ETF
Weight0.02%
Market value‪278.04 K‬
FESM
Fidelity Enhanced Small Cap Core ETF
Weight0.00%
Market value‪270.64 K‬
VTWV
Vanguard Russell 2000 Value ETF
Weight0.02%
Market value‪206.46 K‬
TMED
T. Rowe Price Health Care ETF
Weight0.43%
Market value‪101.21 K‬

Explore more ETFs 

Frequently asked questions


The current price of MPLT is 39.32 USD — it has increased by 3.30% in the past 24 hours. Watch MapLight Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange MapLight Therapeutics, Inc. stocks are traded under the ticker MPLT.
MPLT stock has risen by 9.28% compared to the previous week, the month change is a 33.42% rise, over the last year MapLight Therapeutics, Inc. has showed a 106.95% increase.
We've gathered analysts' opinions on MapLight Therapeutics, Inc. future price: according to them, MPLT price has a max estimate of 60.00 USD and a min estimate of 30.00 USD. Watch MPLT chart and read a more detailed MapLight Therapeutics, Inc. stock forecast: see what analysts think of MapLight Therapeutics, Inc. and suggest that you do with its stocks.
MPLT reached its all-time high on Jul 10, 2026 with the price of 40.43 USD, and its all-time low was 12.24 USD and was reached on Nov 26, 2025. View more price dynamics on MPLT chart.
See other stocks reaching their highest and lowest prices.
MPLT stock is 10.63% volatile and has beta coefficient of 1.37. Track MapLight Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is MapLight Therapeutics, Inc. there?
Today MapLight Therapeutics, Inc. has the market capitalization of ‪1.70 B‬, it has increased by 12.89% over the last week.
Yes, you can track MapLight Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
MapLight Therapeutics, Inc. is going to release the next earnings report on Sep 2, 2026. Keep track of upcoming events with our Earnings Calendar.
MPLT earnings for the last quarter are −1.34 USD per share, whereas the estimation was −1.05 USD resulting in a −27.89% surprise. The estimated earnings for the next quarter are −1.32 USD per share. See more details about MapLight Therapeutics, Inc. earnings.
MapLight Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
MPLT net income for the last quarter is ‪−60.67 M‬ USD, while the quarter before that showed ‪−79.55 M‬ USD of net income which accounts for 0.00% change. Track more MapLight Therapeutics, Inc. financial stats to get the full picture.
No, MPLT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jul 11, 2026, the company has 133 employees. See our rating of the largest employees — is MapLight Therapeutics, Inc. on this list?
Like other stocks, MPLT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MapLight Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MapLight Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MapLight Therapeutics, Inc. stock shows the strong buy signal. See more of MapLight Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.